Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Bacterial Infection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of a Single Dose of CRS3123

NCT01551004
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
CRS3123, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jun 11, 2026, 1:01 AM EDT
Recruiting Phase 1 Interventional

Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents

NCT07092813
View directory record Official record
Conditions
Pharmacokinetics After Oral Intake
Interventions
sulopenem etzadroxil and probenecid
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 11, 2026, 1:01 AM EDT
Active, not recruiting Not applicable Interventional

Efficacy of A Novel RinSe Device to Reduce Oral Bacteria in Intubated IntEnsive CaRe Patients: a Pilot Study

NCT06193512
View directory record Official record
Conditions
Oral Bacterial Infection, Mechanical Ventilation Complication
Interventions
SwishKit + Oral care treatment as usual, Oral care treatment as usual
Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

NCT03450187
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jun 11, 2026, 1:01 AM EDT
Terminated Phase 4 Interventional

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

NCT03040687
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC), B7A- CS6-expressing ETEC challenge strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jun 11, 2026, 1:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Not applicable Interventional

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

NCT00001990
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

NCT02257918
View directory record Official record
Conditions
Gonorrhoea
Interventions
AZD0914, Ceftriaxone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jun 11, 2026, 1:01 AM EDT
Completed No phase listed Observational

New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

NCT00342589
View directory record Official record
Conditions
Pneumocystis Infection, Infection, Pneumonia, Pneumocystis, Lung Disease, Fungal, Mycoses
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT02218372
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
Up to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection

NCT05584683
View directory record Official record
Conditions
Pediatric, Bacterial Infections
Interventions
Amoxicillin potassium clavulanate, Amoxicillin potassium clavulanate (Augmentin ES-600)
Drug
Lead sponsor
Kaizen Bioscience Co.
Industry
Eligibility
3 Months to 24 Months
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

NCT03253094
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Fluconazole, SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 3 Interventional

Treatment of Bacterial Vaginosis With Oral Tinidazole

NCT00229216
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Tinidazole
Drug
Lead sponsor
Mission Pharmacal
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Not applicable Interventional

The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS

NCT00000717
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Primaquine, Clindamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

NCT04160260
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Omadacycline
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Clearwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

NCT05217537
View directory record Official record
Conditions
Bacterial Infections
Interventions
Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
8 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 11, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

NCT02813694
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Beverly Hills, California • Fresno, California • Northridge, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jun 11, 2026, 1:01 AM EDT